Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.63 |
| ▸ | BRD4 | O60885 | 2/20 | 0.63 |
| ▸ | MAPK10 | P53779 | 6/20 | 0.61 |
| ▸ | JUN | P05412 | 3/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.61 |
| ▸ | TTK | P33981 | 3/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.53 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | CDK4 | P11802 | 1/20 | 0.50 |
| ▸ | CCND1 | P24385 | 1/20 | 0.50 |
| ▸ | CCND2 | P30279 | 1/20 | 0.50 |
| ▸ | CCND3 | P30281 | 1/20 | 0.50 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16823053 | 1.00 | JAK2 (0.63) | JAK2BRD4MAPK10JUNMAPK8 | |
| SCHEMBL29847439 | 0.86 | MAPK10 (0.79) | JAK2BRD4MAPK10JUNMAPK8 | |
| SCHEMBL16513631 | 0.86 | MAPK10 (0.79) | JAK2BRD4MAPK10JUNMAPK8 | |
| SCHEMBL16513553 | 0.85 | JUN (0.66) | JAK2BRD4MAPK10JUNMAPK8 | |
| SCHEMBL16514118 | 0.84 | JAK2 (0.62) | JAK2BRD4MAPK10JUNMAPK8 | |
| SCHEMBL29847699 | 0.84 | JAK2 (0.62) | JAK2BRD4MAPK10JUNMAPK8 | |
| SCHEMBL16514829 | 0.82 | BRD4 (0.53) | JAK2BRD4MAPK10JUNMAPK8 | |
| SCHEMBL29575830 | 0.81 | JAK2 (0.66) | JAK2BRD4MAPK10JUNMAPK8 | |
| SCHEMBL29576100 | 0.80 | JAK2 (0.67) | JAK2BRD4MAPK10JUNMAPK8 | |
| SCHEMBL18377046 | 0.79 | BRD4 (0.63) | JAK2BRD4MAPK10JUNMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC | 2024-06-20 | — | — | US | disclosed |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2022-11-10 | — | — | US | disclosed |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | JAK2 356/4885BRD4 474/4885MAPK10 347/4885 |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | JAK2 356/4885BRD4 474/4885MAPK10 347/4885 |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | JAK2 356/4885BRD4 474/4885MAPK10 347/4885 |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | JAK2 356/4885BRD4 474/4885MAPK10 347/4885 |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | JAK2 356/4885BRD4 474/4885MAPK10 347/4885 |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | BRAF, TTK, MAP4K2 | JAK2 155/4885BRD4 1922/4885MAPK10 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.